The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Additionally, HSK31858 rapidly and sustainably reduced the 24-hour sputum volume in patients with bronchiectasis [compared with baseline, the sputum volume decreased by 7.46 g (SE 2.42) in the 20 ...